Darryl May criticizes FDA for restricting access to Replimune melanoma drug
Updated
Updated · The Wall Street Journal · Apr 28
Darryl May criticizes FDA for restricting access to Replimune melanoma drug
11 articles · Updated · The Wall Street Journal · Apr 28
May, a resident of Johns Island, South Carolina, argues the FDA’s restriction is an intentional affliction rather than an accident.
He references a patient in remission for three years who laments that others cannot access the life-changing medication due to the FDA’s decision.
The criticism follows ongoing debate about regulatory barriers affecting patient access to innovative cancer treatments, highlighting tensions between oncologists, patients, and federal regulators.
As a key FDA director exits, will the door reopen for controversial rare disease therapies?
A company says its drug saves lives, but the FDA cites flawed data. Who is right?
Could new data next month force the FDA to reverse its controversial melanoma drug rejection?
With its review system in 'chaos,' can the FDA be trusted with life-saving drug approvals?
While new cancer drugs face hurdles, are minority patients being left even further behind?